337915-79-4

Usage

Uses

Used in Industrial Synthesis:
1,2-Benzenediamine, 4-Bromo-N2-Methylis used as a key intermediate in the synthesis of various organic compounds for different applications. Its unique structure and reactivity make it a valuable building block in the production of pharmaceuticals, agrochemicals, dyes, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1,2-Benzenediamine, 4-Bromo-N2-Methylis utilized as a starting material for the development of new drugs and active pharmaceutical ingredients. Its versatile chemical properties allow for the creation of novel therapeutic agents with potential applications in various medical fields.
Used in Agrochemical Industry:
1,2-Benzenediamine, 4-Bromo-N2-Methylis employed as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its reactivity and ability to form stable derivatives make it suitable for the development of effective and environmentally friendly crop protection products.
Used in Dye Industry:
In the dye industry, 1,2-Benzenediamine, 4-Bromo-N2-Methylis used as a raw material for the production of various dyes and pigments. Its aromatic structure and functional groups enable the creation of dyes with specific color properties and stability, suitable for use in textiles, plastics, and other applications.
Used in Research and Development:
1,2-Benzenediamine, 4-Bromo-N2-Methylis also used in research and development laboratories for the exploration of new chemical reactions and the synthesis of novel compounds. Its unique properties make it an interesting subject for scientific studies and the development of innovative applications in various fields.

InChI:InChI=1/C7H9BrN2/c1-10-7-4-5(8)2-3-6(7)9/h2-4,10H,9H2,1H3

Upstream product

• 302800-13-1 5-bromo-N-methyl-2-nitroaniline 
• 5228-61-5 5-bromo-2-nitroaniline 
• 367-24-8 4-bromo-2-fluoroaniline 
• 875-51-4 4-Bromo-2-nitroaniline 
• 53484-26-7 N-methyl-4-bromo-2-nitroaniline 
• 321-23-3 4-bromo-2-fluoronitrobenzene 

Downstream Products

• 53484-16-5 6-bromo-1-methyl-1H-benzo[d]imidazole 
• 1616059-85-8 C₁₇H₁₆N₂O₂ 
• 1616059-76-7 3-(1-methyl-1H-benzo[d]imidazol-6-yl)phenol 
• 1616059-77-8 1-methyl-6-(3-(oxiran-2-ylmethoxy)phenyl)-1H-benzo[d]imidazole 
• 84712-08-3 5-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazole-2-one 
• 305790-48-1 6-bromo-1-methyl-1,3-dihydro-2H-benzo[d]imidazole-2-one 

Relevant academic research and scientific papers

1H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS

The present invention relates to lH-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

Cu-Catalyzed C-H Allylation of Benzimidazoles with Allenes

CuH-catalyzed intramolecular cyclization and intermolecular allylation of benzimidazoles with allenes have been described. The reaction proceeded smoothly with the catalytic system of Cu(OAc)2/Xantphos and catalytic amount of (MeO)2MeSiH. This protocol features mild reaction conditions and a good tolerance of substrates bearing electron-withdrawing, electron-donating, or electron-neutral groups. A new catalytic mechanism was proposed for this copper hydride catalytic system.

STAT DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

MDM2 DEGRADERS AND USES THEREOF

The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

Benzopyrazine compound, and preparation method and application thereof

A preparation method of a benzopyrazine compound comprises the following steps: dissolving 5-bromo-2-nitroaniline in an organic solvent, then adding an alkali and a methylation reagent, and reacting for a period of time at room temperature to obtain an intermediate III; dissolving the intermediate III in an organic solvent, adding a reducing reagent, and reacting at room temperature for a period of time to obtain an intermediate IV; dissolving the intermediate IV in an organic solvent, adding the alkali and 1,2-dibromoethane, and carrying out a heating reaction for a period of time to obtain an intermediate V; dissolving the intermediate V in an organic solvent, adding the alkali and isopropyl bromide, and heating to react for a period of time to obtain an intermediate VI; dissolving the intermediate VI in an organic solvent, adding bis(pinacolato)diboron, a palladium catalyst and the alkali, and heating to react for a period of time to obtain an intermediate VII; and dissolving the intermediate VII in an organic solvent, adding a 5-bromopyridine derivative, a palladium catalyst and the alkali, and heating to react for a period of time to obtain the benzopyrazine compound. The benzopyrazine compound provided by the invention can be used as a PI3K inhibitor for anticancer treatment.

MERTK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

SYK INHIBITOR AND USE METHOD THEREFOR

Provided are a Syk inhibitor and a use method therefor, and in particular, disclosed are quinolinone represented by formula (I) or quinazoline derivatives or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition, and uses in preparing a medicament for treatment of Syk receptor related diseases.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.